Reference
1. Ross, C. A., E. H. Aylward, E. J. Wild, D. R. Langbehn, J. D. Long, J. H. Warner, et al. 2014. Huntington disease: Natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 10: 204–216.
2. Liu, D., J. D. Long, Y. Zhang, L. A. Raymond, K. Marder, A.Rosser, et al. 2015. Motor onset and diagnosis in Huntington disease using the diagnostic confidence level. J. Neurol. 262: 2691–2698.
3. Bates, G. P., R. Dorsey, J. F. Gusella, M. R. Hayden, C. Kay, B. R. Leavitt, et al. 2015. Huntington disease. Nat. Rev. Dis Primers, 1:15005.
4. Ross, C. A., and S. J. Tabrizi, 2011. Huntington’s disease: From molecular pathogenesis to clinical treatment. Lancet. Neurol. 10: 83–98.
5. Johanssen, T., N. Suphantarida, P. S. Donnelly, X. M. Liu, S. Petrou, A. F. Hill, et al. 2015. PBT2 inhibits glutamate-induced excitotoxicity in neurons through metal-mediated preconditioning. Neurobiol. Dis. 81: 176–185.
6. Cankurtaran, E. S., E. Ozalp, H. Soygur, and A. Cakir, 2006. Clinical experience with risperidone and memantine in the treatment of Huntington’s disease. J. Natl. Med. Assoc. 98: 1353–1355.
7. Leavitt, B., and Huntington Study Group. 2011. A trial of memantine as symptomatic treatment for early Huntington disease (MITIGATE-HD). Clinical. Trials. gov. database. Identifier. NCT01458470.
8. Aguilar, L., C. Lorenzo, R. Fernández-Ovejero, C. Roncero, and A. L. Montejo, 2019. Tardive dyskinesia after aripiprazole treatment that improved with tetrabenazine, clozapine, and botulinum toxin. Front in Pharmacol. 10: 281.
9. Kitagawa, N., and A. Takeuchi, 2014. Memantine-induced myoclonus. Neurology. 83: 1387.
10. Milnerwood, A. J., C. M. Gladding, M. A. Pouladi, A. M. Kaufman, R. M. Hines, J. D. Boyd, et al. 2010. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington’s disease mice. Neuron. 65: 178–190.